Study title: An open-labelled, multicentred study of mizolastine (SL85.0324-00) (10mg and 15mg/d) to assess the long-term safety and long-term efficacy in patients suffering from perennial allergic rhinoconjunctivitis (RIPEREX Study). - Scadding G. Tasman A.J. Dunmore C. Favennec E. Mathieu G. Steinerstauch P. Weber F.- 10/06/1998
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report, Please see report | |||||
| Assessment: | |||||
| Active substance: MIZOLASTINE | |||||
| ATC code: | |||||
| Document link: Mizolastine STUDY 94-00939-EN-01.xls | |||||
| Document date: 2013-03-15 | |||||
| Study number: 94-00939-EN-01 | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |